MiNK Therapeutics, Inc. (INKT)

Nasdaq Biotechnology Diagnostics SIC: 2836
D
Pipeline Grade

Financial Position (from SEC Filings)

$9.5M
Cash & Equivalents
$1.7M
Quarterly Burn Rate
16 mo
Est. Cash Runway
$55M
Market Cap

Estimated from most recent SEC quarterly filing. View SEC filings

Drug Pipeline (0 Assets)

No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.

Upcoming Catalysts

No upcoming catalysts detected for this company.

Active Clinical Trials (1)

NCT #TitlePhaseStatusEnrollment
NCT03655223 Early Check: Expanded Screening in Newborns OTHER Active Not Recruiting 30,000

Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.

More Analysis

AI Stock Score

SEC EDGAR fundamental analysis with Claude AI & ChatGPT ratings for INKT.

SEC EDGAR Filings

All SEC filings for MiNK Therapeutics, Inc. on EDGAR.

Full Calendar

View all upcoming FDA catalysts across all biotech companies.